Idera Pharmaceuticals (IDRA) News $IDRA
Insider Buying Is On The Rise In These 4 Rallying Stocks
at The Street - Thu Mar 20, 5:16PM CDT
James Dennin, Kapitall: One way to evaluate small cap stocks is by looking for insider buying, when people on staff are buying [...]
New Highs & Stocks to Watch -- Research on Penn Virginia, Idera Pharma, US Geothermal, and First Republic Bank
PR Newswire - Wed Mar 19, 7:23AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite finished at 4,333.31, up 1.25%. The Dow Jones Industrial Average closed the session at 16,336.19, up 0.55% and the S&P 500 ended the day at 1,872.25, higher by 0.72%. The gains were broad based with 9 of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Penn Virginia Corp. (NYSE: PVA), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), US Geothermal Inc. (AMEX: HTM), and First Republic Bank (NYSE: FRC). Free technical research on PVA, IDRA, HTM and FRC can be downloaded upon signing up at:
Idera Pharmaceuticals Shares Up 20.5% Since SmarTrend's Buy Recommendation (IDRA)
Comtex SmarTrend(R) - Mon Mar 17, 5:40PM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 20.48% as of today's recent price of $6.06.
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update
Business Wire - Thu Mar 13, 6:50AM CDT
--- Details announced for planned clinical development of IMO-8400 in polymyositis and dermatomyositis -
Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases
Business Wire - Thu Mar 13, 6:35AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. The Company plans to submit a protocol to the U.S. Food and Drug Administration (FDA) in the first half of 2014 for a Phase 1/2 clinical trial to investigate the safety and potential utility of IMO-8400 in these two indications. This represents the execution of a previously announced strategy to expand the clinical development of IMO-8400 in orphan autoimmune disease indications. Based on the results from this study, Idera anticipates that it will pursue separate later-stage clinical trials for each indication.
Idera Pharmaceuticals names Baker Brothers Investments' executives to board
M2 - Thu Mar 13, 4:01AM CDT
Biopharmaceutical company Idera Pharmaceuticals (NasdaqCM:IDRA) disclosed on Wednesday the addition of two Baker Brothers Investments' executives to its board of directors.
Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors
Business Wire - Wed Mar 12, 7:30AM CDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments' Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014. Founded in 2000, Baker Brothers Investments manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments and foundations.
17.7% Return Seen to Date on SmarTrend Idera Pharmaceuticals Call (IDRA)
Comtex SmarTrend(R) - Mon Mar 10, 11:18AM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 17.65% as of today's recent price of $5.92.
Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
Business Wire - Thu Mar 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Uptrend Call Working As Idera Pharmaceuticals Stock Rises 14.1% (IDRA)
Comtex SmarTrend(R) - Mon Mar 03, 9:59AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 3 weeks, Idera Pharmaceuticals has returned 14.12% as of today's recent price of $5.74.
Idera to Present at the Cowen & Co. 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley Place in Boston, MA.
Idera Pharmaceuticals Up 16.0% Since SmarTrend Uptrend Call (IDRA)
Comtex SmarTrend(R) - Mon Feb 24, 9:26AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 2 weeks, Idera Pharmaceuticals has returned 15.98% as of today's recent price of $5.83.
Idera to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 3:02PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City.
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Mon Feb 10, 3:15PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant, which is the per share public offering price for the common stock less the $0.01 per share exercise price. The shares of common stock in the offering include 1,026,188 shares issued upon the exercise in full by the underwriters of their over-allotment option at the offering price. The gross proceeds to Idera from this offering are expected to be approximately $40.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants.
2 Biotech Stocks Under $10 in Breakout Territory
at The Street - Fri Feb 07, 8:24AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
Idera to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Thu Feb 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. EST at the Waldorf Astoria in New York City.
Idera Pharmaceuticals Inc prices public offering of common stock and pre-funded warrants at USD4.00 per share
M2 - Thu Feb 06, 5:26AM CST
Therapeutics company Idera Pharmaceuticals Inc (NasdaqCM:IDRA) said on Wednesday that it has priced its public offering of 6,841,250 shares of common stock at USD4.00 per share.
Stock to Watch: Idera Pharmaceuticals Down 8.6% (IDRA)
Comtex SmarTrend(R) - Wed Feb 05, 10:42AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 8.6% to $3.84 on 1.0x average daily volume. Thus far today, Idera Pharmaceuticals has traded 2.8 million shares, vs. average volume of 2.8 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's -0.1%) and underperformed the S&P 500 (-8.6% to the S&P's -0.4%) during today's trading.
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Wed Feb 05, 8:09AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Idera from this offering are expected to be approximately $36 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,026,188 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about February 10, 2014, subject to customary closing conditions.
Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Tue Feb 04, 3:01PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Insider Buying Is On The Rise In These 4 Rallying Stocks
at The Street - Thu Mar 20, 5:16PM CDT
James Dennin, Kapitall: One way to evaluate small cap stocks is by looking for insider buying, when people on staff are buying [...]
New Highs & Stocks to Watch -- Research on Penn Virginia, Idera Pharma, US Geothermal, and First Republic Bank
PR Newswire - Wed Mar 19, 7:23AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite finished at 4,333.31, up 1.25%. The Dow Jones Industrial Average closed the session at 16,336.19, up 0.55% and the S&P 500 ended the day at 1,872.25, higher by 0.72%. The gains were broad based with 9 of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Penn Virginia Corp. (NYSE: PVA), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), US Geothermal Inc. (AMEX: HTM), and First Republic Bank (NYSE: FRC). Free technical research on PVA, IDRA, HTM and FRC can be downloaded upon signing up at:
Idera Pharmaceuticals Shares Up 20.5% Since SmarTrend's Buy Recommendation (IDRA)
Comtex SmarTrend(R) - Mon Mar 17, 5:40PM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 20.48% as of today's recent price of $6.06.
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update
Business Wire - Thu Mar 13, 6:50AM CDT
--- Details announced for planned clinical development of IMO-8400 in polymyositis and dermatomyositis -
Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases
Business Wire - Thu Mar 13, 6:35AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. The Company plans to submit a protocol to the U.S. Food and Drug Administration (FDA) in the first half of 2014 for a Phase 1/2 clinical trial to investigate the safety and potential utility of IMO-8400 in these two indications. This represents the execution of a previously announced strategy to expand the clinical development of IMO-8400 in orphan autoimmune disease indications. Based on the results from this study, Idera anticipates that it will pursue separate later-stage clinical trials for each indication.
Idera Pharmaceuticals names Baker Brothers Investments' executives to board
M2 - Thu Mar 13, 4:01AM CDT
Biopharmaceutical company Idera Pharmaceuticals (NasdaqCM:IDRA) disclosed on Wednesday the addition of two Baker Brothers Investments' executives to its board of directors.
Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors
Business Wire - Wed Mar 12, 7:30AM CDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments' Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014. Founded in 2000, Baker Brothers Investments manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments and foundations.
17.7% Return Seen to Date on SmarTrend Idera Pharmaceuticals Call (IDRA)
Comtex SmarTrend(R) - Mon Mar 10, 11:18AM CDT
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 1 month, Idera Pharmaceuticals has returned 17.65% as of today's recent price of $5.92.
Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
Business Wire - Thu Mar 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Uptrend Call Working As Idera Pharmaceuticals Stock Rises 14.1% (IDRA)
Comtex SmarTrend(R) - Mon Mar 03, 9:59AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 3 weeks, Idera Pharmaceuticals has returned 14.12% as of today's recent price of $5.74.
Idera to Present at the Cowen & Co. 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley Place in Boston, MA.
Idera Pharmaceuticals Up 16.0% Since SmarTrend Uptrend Call (IDRA)
Comtex SmarTrend(R) - Mon Feb 24, 9:26AM CST
SmarTrend identified an Uptrend for Idera Pharmaceuticals (NASDAQ:IDRA) on February 7th, 2014 at $5.03. In approximately 2 weeks, Idera Pharmaceuticals has returned 15.98% as of today's recent price of $5.83.
Idera to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Tue Feb 18, 3:02PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City.
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Mon Feb 10, 3:15PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant, which is the per share public offering price for the common stock less the $0.01 per share exercise price. The shares of common stock in the offering include 1,026,188 shares issued upon the exercise in full by the underwriters of their over-allotment option at the offering price. The gross proceeds to Idera from this offering are expected to be approximately $40.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants.
2 Biotech Stocks Under $10 in Breakout Territory
at The Street - Fri Feb 07, 8:24AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
Idera to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Thu Feb 06, 7:30AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. EST at the Waldorf Astoria in New York City.
Idera Pharmaceuticals Inc prices public offering of common stock and pre-funded warrants at USD4.00 per share
M2 - Thu Feb 06, 5:26AM CST
Therapeutics company Idera Pharmaceuticals Inc (NasdaqCM:IDRA) said on Wednesday that it has priced its public offering of 6,841,250 shares of common stock at USD4.00 per share.
Stock to Watch: Idera Pharmaceuticals Down 8.6% (IDRA)
Comtex SmarTrend(R) - Wed Feb 05, 10:42AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 8.6% to $3.84 on 1.0x average daily volume. Thus far today, Idera Pharmaceuticals has traded 2.8 million shares, vs. average volume of 2.8 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's -0.1%) and underperformed the S&P 500 (-8.6% to the S&P's -0.4%) during today's trading.
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Wed Feb 05, 8:09AM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Idera from this offering are expected to be approximately $36 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,026,188 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about February 10, 2014, subject to customary closing conditions.
Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants
Business Wire - Tue Feb 04, 3:01PM CST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) ("Idera" or the "Company") today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
